fda bans tirzepatide Is Legal in 2026? Status, Compounding Ban & FDA bans compounded GLP1 medications,

Due to its copper content, the peptide may appear in varying shades of blue without affecting consistency or analytical profile

The FDA placed it in 503A Category 2 ("may present significant safety risks") in 2023, effectively barring compounding pharmacies from using it, then removed it from that category in April 2026 after nominators withdrew their submission, without adding it to the approved Category 1 compounding list

For guidance on storage conditions that preserve compound integrity from lyophilized powder through reconstitution, see TB-500 research overview for a compound-level example of how storage intersects with research handling

However, the combination requires baseline medical evaluation and ongoing provider monitoring due to potential drug interactions and contraindications

This includes things like vitamins and herbal supplements, as they can have unanticipated interactions with your prescribed medications

One of the most critical concerns involves anaphylaxis